Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hypertriglyceridemia leads to liver steatosis, cardiovascular disease, and type 2 diabetes. Although
HCBP6
(
hepatitis C virus core-binding protein 6
) was previously shown to be an HCV (hepatitis C virus) core-binding protein, its biological function remains unclear. Here, we demonstrate that
HCBP6
negatively regulates intracellular triglyceride (TG) levels in hepatocytes. We found that bidirectional manipulation of hepatocyte
HCBP6
expression by knockdown or overexpression results in increased or decreased TG accumulation, respectively. In addition,
HCBP6
mRNA and protein levels exhibited significant time- and dose-dependent increases in a cellular model of lipid-overload
hepatic steatosis
. Furthermore, TG levels are regulated by
HCBP6
-sterol regulatory element binding protein 1c (SREBP1c)-mediated fatty acid synthase (FASN) expression. We also demonstrate that
HCBP6
mRNA and protein expression is inhibited by microRNA-122 (miR-122), and miR-122 overexpression elicited more robust translational repression of luciferase activity driven by the full 3'-UTR of
HCBP6
. Taken together, our results provide new evidence that miR-122-regulated
HCBP6
functions as a sensor protein to maintain intrahepatocyte TG levels.
...
PMID:HCBP6 Modulates Triglyceride Homeostasis in Hepatocytes Via the SREBP1c/FASN Pathway. 2585 6